193 related articles for article (PubMed ID: 11826788)
1. [Choice of triptan in migraine].
Salvesen R
Tidsskr Nor Laegeforen; 2001 Nov; 121(29):3410-1. PubMed ID: 11826788
[No Abstract] [Full Text] [Related]
2. Clinical applications of new therapeutic deliveries in migraine.
Dahlöf C
Neurology; 2003 Oct; 61(8 Suppl 4):S31-4. PubMed ID: 14581656
[TBL] [Abstract][Full Text] [Related]
3. Sumatriptan and naratriptan tolerability and safety: an update of post-marketing experience.
Welch KM
Cephalalgia; 2001; 21 Suppl 1():25-8. PubMed ID: 11678818
[No Abstract] [Full Text] [Related]
4. Sumatriptan-induced chest symptoms in Japanese.
Hirata K
Intern Med; 2002 Aug; 41(8):599-600. PubMed ID: 12211521
[No Abstract] [Full Text] [Related]
5. Building on the sumatriptan experience: the development of naratriptan.
Connor HE
Cephalalgia; 2001; 21 Suppl 1():32-4. PubMed ID: 11678820
[No Abstract] [Full Text] [Related]
6. Would any acute treatment for migraine demonstrate recurrence?
Dahlöf C
Cephalalgia; 1997 Jun; 17 Suppl 17():17-9; discussion 19-20. PubMed ID: 9218881
[No Abstract] [Full Text] [Related]
7. Onzetra Xsail--sumatriptan nasal powder.
Med Lett Drugs Ther; 2016 Jul; 58(1499):92-3. PubMed ID: 27403783
[No Abstract] [Full Text] [Related]
8. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan.
Siegel SJ; O'Neill C; Dubé LM; Kaldeway P; Morris R; Jackson D; Sebree T
Pharm Res; 2007 Oct; 24(10):1919-26. PubMed ID: 17577644
[TBL] [Abstract][Full Text] [Related]
9. [Cardiovascular side-effects of triptanes in migraine exist but are rare. 5-HT receptor mediated extracranial vasoconstriction is the most common cause].
Hedenmalm K
Lakartidningen; 2000 Jun; 97(25):3078-84. PubMed ID: 10911703
[TBL] [Abstract][Full Text] [Related]
10. How to assess patient preference of migraine treatments.
Dahlöf C
Cephalalgia; 1999 Jul; 19 Suppl 24():2-5; discussion 5-6. PubMed ID: 10526675
[No Abstract] [Full Text] [Related]
11. Vasospasm-induced myocardial infarction with sumatriptan.
Mueller L; Gallagher RM; Ciervo CA
Headache; 1996 May; 36(5):329-31. PubMed ID: 8682677
[TBL] [Abstract][Full Text] [Related]
12. Commentary.
Rothrock JF
Headache; 2011 Apr; 51(4):518-9. PubMed ID: 21457236
[No Abstract] [Full Text] [Related]
13. Migraine revolution and sumatriptan.
Palmer JB; Salonen R
Lancet; 2000 Jun; 355(9222):2250-1. PubMed ID: 10881915
[No Abstract] [Full Text] [Related]
14. Triptans and migraine.
Bateman DN
Lancet; 2000 Mar; 355(9207):860-1. PubMed ID: 10752697
[No Abstract] [Full Text] [Related]
15. [Drug-clinics. The drug of the month. Imitrex nasal spray (sumatriptan)].
Scheen AJ
Rev Med Liege; 1997 Sep; 52(9):610-2. PubMed ID: 9441347
[No Abstract] [Full Text] [Related]
16. [New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses].
Dahlöf CG
Lakartidningen; 1998 Nov; 95(46):5175, 5178-82, 5184-6. PubMed ID: 9842191
[TBL] [Abstract][Full Text] [Related]
17. Where do triptans act in the treatment of migraine?
Ahn AH; Basbaum AI
Pain; 2005 May; 115(1-2):1-4. PubMed ID: 15836963
[No Abstract] [Full Text] [Related]
18. Tolerability of sumatriptan: clinical trials and postmarketing experience.
Allen C; Dayno J
Cephalalgia; 2001 Oct; 21(8):855-6. PubMed ID: 11737014
[No Abstract] [Full Text] [Related]
19. A case of sumatriptan-induced intestinal ischemia.
Repaka A; Wenger J; Sitaraman SV
J Gastroenterol; 2006 Feb; 41(2):177-8. PubMed ID: 16568377
[No Abstract] [Full Text] [Related]
20. Cerebral vasospasm from sumatriptan.
Dash S; Bogdanova O; Xavier A; Farkas J; Pullicino P
Neurology; 2004 Dec; 63(11):2128. PubMed ID: 15596760
[No Abstract] [Full Text] [Related]
[Next] [New Search]
